Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Janssen submits Marketing Authorization Application for Ibrutinib

Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.

30 Oct 2013

Lymphoma Hub launched for hematologists, oncologists treating lymphoma

Led by La Fondazione Italiana Linfomi, a non-profit Italian professional lymphoma research organization, and supported by an unrestricted educational grant from Celgene Corporation, the Lymphoma Hub has been launched as a new online community for hematologists and oncologists treating lymphoma.

29 Oct 2013

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Study evaluates sexual well-being in SCT survivors using sexual function assessment tools

New research ties preparative procedures and complications associated with blood or bone marrow transplantation (stem cell transplantation, SCT) with diminished sexual health in both men and women who have undergone the lifesaving procedure. Study data, published online today in Blood, the Journal of the American Society of Hematology, confirm chronic graft-versus-host disease, a serious complication that occurs when donor cells attack the recipient's cells, as a potential source of sexual dysfunction and are the first to demonstrate an association between total body irradiation and sexual dysfunction in men.

25 Oct 2013

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.

23 Oct 2013

Carcinogens detected in emissions downwind of 'Industrial Heartland'

Levels of contaminants higher than in some of the world's most polluted cities have been found downwind of Canada's largest oil, gas and tar sands processing zone, in a rural area where men suffer elevated rates of cancers linked to such chemicals.

23 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Cell Therapeutics, Inc. (CTI) today announced the presentation of findings from a preclinical study of PIXUVRI® (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.

21 Oct 2013

Study finds inherited GATA3 gene variation increases risk of developing pediatric leukemia

Research led by St. Jude Children's Research Hospital scientists has linked an inherited gene variation to a nearly four-fold increased risk of developing a pediatric acute lymphoblastic leukemia (ALL) subtype that is associated with a poor outcome.

21 Oct 2013

Five Research Units established to uncover physiological basis for cognitive processes, cultural techniques

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing five new Research Units. This was decided by the DFG Senate at its October meeting. The purpose of the research collaborations is to offer researchers the possibility to pursue current, pressing issues in their subject areas and to establish innovative work directions.

19 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Light pulses stimulate designer peptides to trigger death pathway in cancerous cells

Researchers at Cardiff University have created a peptide (a small piece of protein), linked to a light-responsive dye, capable of switching 'on' death pathways in cancer cells. The peptide remains inactive until exposed to external light pulses which convert it into a cell death signal.

17 Oct 2013

UCSD professor receives $6.25M grant to support research on chronic lymphocytic leukemia

The Leukemia & Lymphoma Society has awarded Thomas J. Kipps, MD, PhD, Distinguished Professor of Medicine at the University of California, San Diego School of Medicine, with a 5-year, $6.25 million Specialized Center of Research program grant to support research on chronic lymphocytic leukemia (CLL), the most common adult leukemia in the United States.

16 Oct 2013

Promising new type of cancer treatment to benefit more patients

More patients than ever stand to benefit from a promising new type of cancer treatment, after scientists compiled a library of molecules that can prime patients’ immune systems to fight a range of cancers including leukaemia, myeloma, lung cancer and skin cancer.

15 Oct 2013

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced that the National Institute for Health and Care Excellence, a non-departmental public body of the Department of Health in the United Kingdom, issued second draft guidance on PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

15 Oct 2013

UC San Diego researcher awarded grant to advance research on chronic lymphocytic leukemia

The Leukemia & Lymphoma Society has awarded Thomas J. Kipps, MD, PhD, Distinguished Professor of Medicine at the University of California, San Diego School of Medicine, with a 5-year, $6.25 million Specialized Center of Research program grant to support research on chronic lymphocytic leukemia, the most common adult leukemia in the United States.

15 Oct 2013

Study provides novel link between cellular aging and diffuse large B-cell lymphoma

Scientists at the University of Massachusetts Medical School have shown that diffuse large B-cell lymphoma (DLBCL) may be susceptible to treatment by re-activating the normal aging program in tumor cells so they can no longer divide.

15 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Canadian discovery could lead to development of vaccine against Epstein-Barr virus

Development of a vaccine against Epstein-Barr virus has taken a step forward with the Canadian discovery of how EBV infection evades detection by the immune system.

12 Oct 2013

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Cancer immunotherapy can successfully use the body's own immune system to kill tumor cells. But some current approaches to stimulate an antitumor immune response are short-lived, with limited clinical effectiveness. A new gene transfer strategy that introduces modified, immune-stimulating human stem cells is both feasible and effective for achieving persistent immunotherapy to treat leukemias and lymophomas, according to a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

11 Oct 2013

Lymphoma News and Research

Further Reading

Janssen submits Marketing Authorization Application for Ibrutinib

Lymphoma Hub launched for hematologists, oncologists treating lymphoma

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Study evaluates sexual well-being in SCT survivors using sexual function assessment tools

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

Carcinogens detected in emissions downwind of 'Industrial Heartland'

New investigational drug offers potential treatment option for lung cancer

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Study finds inherited GATA3 gene variation increases risk of developing pediatric leukemia

Five Research Units established to uncover physiological basis for cognitive processes, cultural techniques

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Light pulses stimulate designer peptides to trigger death pathway in cancerous cells

UCSD professor receives $6.25M grant to support research on chronic lymphocytic leukemia

Promising new type of cancer treatment to benefit more patients

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

UC San Diego researcher awarded grant to advance research on chronic lymphocytic leukemia

Study provides novel link between cellular aging and diffuse large B-cell lymphoma

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Canadian discovery could lead to development of vaccine against Epstein-Barr virus

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News